MIM
CMPX icon

MetLife Investment Management’s Compass Therapeutics CMPX Stock Holding History

MetLife Investment Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Buy
71,421
+7,216
+11% +$21.3K ﹤0.01% 2541
2026
Q1 		$340K Sell
64,205
-9,780
-13% -$56.5K ﹤0.01% 1945
2025
Q4 		$397K Buy
73,985
+15,638
+27% +$72.2K ﹤0.01% 1900
2025
Q3 		$204K Sell
58,347
-599
-1% -$1.89K ﹤0.01% 2305
2025
Q2 		$153K Buy
58,946
+21,779
+59% +$44.9K ﹤0.01% 2326
2025
Q1 		$70.6K Sell
37,167
-25,974
-41% -$69.1K ﹤0.01% 2645
2024
Q4 		$91.6K Buy
63,141
+42,115
+200% +$69.9K ﹤0.01% 2657
2024
Q3 		$38.7K Sell
21,026
-3,351
-14% -$4.18K ﹤0.01% 2781
2024
Q2 		$24.4K Sell
24,377
-26,153
-52% -$38.2K ﹤0.01% 2861
2024
Q1 		$100K Buy
50,530
+577
+1% +$997 ﹤0.01% 2538
2023
Q4 		$77.9K Hold
49,953
– – ﹤0.01% 2702
2023
Q3 		$98.4K Hold
49,953
– – ﹤0.01% 2587
2023
Q2 		$159K Buy
+49,953
New +$157K ﹤0.01% 2408

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MetLife Investment Management's CMPX Position: Q2 2026 in Review

MetLife Investment Management increased its Compass Therapeutics (CMPX) stake by 11% in Q2 2026, buying an estimated $21.3K and bringing the position to 71,421 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #2541.

MetLife Investment Management first reported a position in CMPX in Q2 2023 and has held it in 13 quarters since. The position peaked at $397K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • MetLife Investment Management held 71,421 shares of Compass Therapeutics worth $156K as of Q2 2026.
  • MetLife Investment Management bought 7,216 Compass Therapeutics shares in Q2 2026, an estimated $21.3K.
  • Compass Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2541 holding.
  • MetLife Investment Management first reported a position in Compass Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • MetLife Investment Management's Compass Therapeutics position peaked at $397K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.